[go: up one dir, main page]

CL2013001987A1 - Polipeptidos interleuquina-2 mutante que comprende una primera mutacion de aminoacido que anula o reduce la afinidad del polipeptido il-2 mutante para receptor il-2 de alta afinidad y conserva afinidad del polipeptido il-2 mutante para receptor il-2 de afinidad intermedia; inmunoconjugado; metodo para producir polipeptido; composicion farmaceutica que lo comprende. - Google Patents

Polipeptidos interleuquina-2 mutante que comprende una primera mutacion de aminoacido que anula o reduce la afinidad del polipeptido il-2 mutante para receptor il-2 de alta afinidad y conserva afinidad del polipeptido il-2 mutante para receptor il-2 de afinidad intermedia; inmunoconjugado; metodo para producir polipeptido; composicion farmaceutica que lo comprende.

Info

Publication number
CL2013001987A1
CL2013001987A1 CL2013001987A CL2013001987A CL2013001987A1 CL 2013001987 A1 CL2013001987 A1 CL 2013001987A1 CL 2013001987 A CL2013001987 A CL 2013001987A CL 2013001987 A CL2013001987 A CL 2013001987A CL 2013001987 A1 CL2013001987 A1 CL 2013001987A1
Authority
CL
Chile
Prior art keywords
affinity
polypeptide
mutant
receptor
nullifies
Prior art date
Application number
CL2013001987A
Other languages
English (en)
Inventor
Ralf Hosse
Christian Klein
Ekkehard Moessner
Anne Freimoser-Grundschober
Oliver Ast
Peter Bruenker
Sylvia Herter
Thomas U Hofer
Valeria B Nicolini
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CL2013001987A1 publication Critical patent/CL2013001987A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6853—Carcino-embryonic antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2013001987A 2011-02-10 2013-07-05 Polipeptidos interleuquina-2 mutante que comprende una primera mutacion de aminoacido que anula o reduce la afinidad del polipeptido il-2 mutante para receptor il-2 de alta afinidad y conserva afinidad del polipeptido il-2 mutante para receptor il-2 de afinidad intermedia; inmunoconjugado; metodo para producir polipeptido; composicion farmaceutica que lo comprende. CL2013001987A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11153964 2011-02-10
EP11164237 2011-04-29

Publications (1)

Publication Number Publication Date
CL2013001987A1 true CL2013001987A1 (es) 2014-01-31

Family

ID=45560919

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001987A CL2013001987A1 (es) 2011-02-10 2013-07-05 Polipeptidos interleuquina-2 mutante que comprende una primera mutacion de aminoacido que anula o reduce la afinidad del polipeptido il-2 mutante para receptor il-2 de alta afinidad y conserva afinidad del polipeptido il-2 mutante para receptor il-2 de afinidad intermedia; inmunoconjugado; metodo para producir polipeptido; composicion farmaceutica que lo comprende.

Country Status (35)

Country Link
US (5) US9266938B2 (es)
EP (4) EP2673294B1 (es)
JP (2) JP5878182B2 (es)
KR (2) KR101852245B1 (es)
CN (3) CN105440123B (es)
AR (1) AR085335A1 (es)
AU (2) AU2012215573B2 (es)
BR (1) BR112013018932B1 (es)
CA (1) CA2824253C (es)
CL (1) CL2013001987A1 (es)
CO (1) CO6741186A2 (es)
CR (1) CR20130314A (es)
CY (1) CY1117842T1 (es)
DK (3) DK3489255T3 (es)
EA (1) EA033369B1 (es)
EC (1) ECSP13012815A (es)
ES (3) ES2694564T3 (es)
HR (3) HRP20160917T1 (es)
HU (3) HUE040326T2 (es)
IL (3) IL269687B (es)
LT (2) LT3075745T (es)
MA (1) MA35803B1 (es)
MX (2) MX356675B (es)
MY (1) MY190604A (es)
PE (2) PE20140303A1 (es)
PH (2) PH12013501657A1 (es)
PL (3) PL2673294T3 (es)
PT (3) PT3489255T (es)
RS (3) RS62238B1 (es)
SG (2) SG10201604160WA (es)
SI (3) SI3489255T1 (es)
TW (2) TWI577801B (es)
UA (2) UA117294C2 (es)
WO (1) WO2012107417A1 (es)
ZA (1) ZA201305282B (es)

Families Citing this family (265)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN103052649B (zh) 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
EA033369B1 (ru) 2011-02-10 2019-10-31 Roche Glycart Ag Мутантные полипептиды интерлейкина-2 со сниженной аффинностью к высокоаффинному рецептору il-2 и неизменной аффинностью к рецептору il-2 с промежуточной аффинностью и их применение
PL2681244T3 (pl) * 2011-03-02 2018-04-30 Roche Glycart Ag Przeciwciała przeciwko antygenowi rakowo-płodowemu
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US9920324B2 (en) 2011-06-01 2018-03-20 Intrexon Actobiotics Nv Polycistronic expression system for bacteria
RU2605390C2 (ru) 2011-08-23 2016-12-20 Рош Гликарт Аг Биспецифические антитела, специфичные к антигенам, активирующим т-клетки, и опухолевому антигену, и способы их применения
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
ES2700978T3 (es) 2012-08-07 2019-02-20 Roche Glycart Ag Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
CA2887486A1 (en) * 2012-11-30 2014-06-05 Roche Glycart Ag Removal of cancer cells by circulating virus-specific cytotoxic t-cells using cancer cell targeted mhc class i comprising multi-function proteins
PL2935328T3 (pl) 2012-12-21 2019-02-28 Hoffmann La Roche Połączone wiązaniem dwusiarczkowym wielowartościowe białka wielofunkcyjne zawierające MHC klasy I
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP6133444B2 (ja) * 2013-02-26 2017-05-24 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
CA2896370A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
WO2014145907A1 (en) 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
LT3041854T (lt) 2013-08-08 2020-03-25 The Scripps Research Institute Nukleorūgščių specifinės vietos žymėjimo fermentais in vitro būdas, įvedant nenatūralius nukleotidus
AU2015215001B2 (en) 2014-02-06 2019-08-15 F. Hoffmann-La Roche Ag Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
HRP20200164T1 (hr) 2014-03-28 2020-05-01 Xencor, Inc. Bispecifična protutijela koja se vežu na cd38 i cd3
TWI638047B (zh) 2014-04-09 2018-10-11 史基普研究協會 藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
ES2989669T3 (es) 2014-07-10 2024-11-27 Univ Zuerich Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana
HUE046065T2 (hu) * 2014-07-21 2020-01-28 Delinia Inc Szabályozó T-sejteket szelektíven aktiváló molekulák autoimmun betegségek kezelésére
EA038958B1 (ru) 2014-08-04 2021-11-15 Ф. Хоффманн-Ля Рош Аг Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
PL3180020T3 (pl) * 2014-08-11 2019-06-28 Delinia, Inc. Modyfikowane warianty il-2, które selektywnie aktywują limfocyty t regulatorowe do leczenia chorób autoimmunologicznych
CA2951604A1 (en) * 2014-08-29 2016-03-03 Pablo Umana Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
LT3224275T (lt) 2014-11-14 2020-05-25 F. Hoffmann-La Roche Ag Antigeną surišančios molekulės, apimančios tnf šeimos ligando trimerą
DK3221356T3 (da) 2014-11-20 2020-11-02 Hoffmann La Roche T-celleaktiverende, bispecifikke, antigenbindende molekyler mod folr1 og cd3
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
CA2968162A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Common light chains and methods of use
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171103A1 (es) 2014-11-26 2017-08-07 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38
DK3223845T3 (da) 2014-11-26 2021-08-16 Xencor Inc Heterodimere antistoffer, der binder cd3 og cd20
DK3233192T3 (da) 2014-12-15 2021-07-19 Univ Washington Sammensætninger og fremgangsmåder til målrettet cytokinindgivelse
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN114751989B (zh) 2015-03-31 2025-03-14 豪夫迈·罗氏有限公司 包含三聚体tnf家族配体的抗原结合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR20180053674A (ko) 2015-10-02 2018-05-23 에프. 호프만-라 로슈 아게 공자극 tnf 수용체에 특이적인 이중특이성 항체
RU2729371C1 (ru) 2015-10-02 2020-08-06 Ф. Хоффманн-Ля Рош Аг Биспецифические антитела, специфические к pd1 и tim3
BR112018000835A2 (pt) 2015-10-02 2018-09-11 Hoffmann La Roche molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
CA3003969A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
RU2018124307A (ru) 2015-12-04 2020-01-14 Новартис Аг Антительно-цитокиновые привитые композиции и способы применения для иммунорегуляции
WO2017100372A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
PL3387015T3 (pl) * 2015-12-09 2022-02-14 F. Hoffmann-La Roche Ag Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
WO2017106767A1 (en) 2015-12-18 2017-06-22 The Scripps Research Institute Production of unnatural nucleotides using a crispr/cas9 system
ES2837428T3 (es) 2016-01-08 2021-06-30 Hoffmann La Roche Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
WO2017122130A1 (en) 2016-01-11 2017-07-20 Novartis Ag Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
JP7292877B2 (ja) 2016-01-14 2023-06-19 イントレクソン・アクトバイオテイクス・エヌブイ １型糖尿病を処置するための組成物および方法
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
DK3411398T3 (da) 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
KR20180117116A (ko) 2016-02-05 2018-10-26 워싱턴 유니버시티 표적화된 사이토카인 전달을 위한 조성물 및 방법들
CA3016849A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
HRP20230528T1 (hr) 2016-03-22 2023-08-04 F. Hoffmann - La Roche Ag Bispecifične molekule t stanica aktivirane proteazom
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
CN109689087B (zh) 2016-05-13 2023-04-04 奥里尼斯生物科学私人有限公司 靶向性突变干扰素-β及其用途
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
DK3475295T3 (da) 2016-06-24 2022-10-24 Scripps Research Inst Hidtil ukendt nukleosidtriphosphat-transportør og anvendelser deraf
EP3475304B1 (en) 2016-06-28 2022-03-23 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
AU2017310163B2 (en) 2016-08-10 2021-09-09 Ajou University Industry-Academic Cooperation Foundation Heterodimeric Fc-fused cytokine and pharmaceutical composition comprising the same
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN110087681A (zh) 2016-09-28 2019-08-02 佐马美国有限公司 结合白细胞介素-2的抗体和其用途
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
CA3040504A1 (en) 2016-10-14 2018-04-19 Xencor, Inc. Il15/il15ra heterodimeric fc-fusion proteins
JP7213180B2 (ja) * 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー 免疫コンジュゲートを製造するための方法
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN110167957A (zh) * 2016-11-08 2019-08-23 德里尼亚公司 用于治疗自身免疫疾病的il-2变体
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
KR102760578B1 (ko) 2016-12-22 2025-02-03 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
JP7586579B2 (ja) 2017-02-06 2024-11-19 オリオンズ バイオサイエンス インコーポレイテッド 標的化改変型インターフェロン及びその使用
EP4431109A3 (en) * 2017-03-15 2024-11-27 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
CN110520436A (zh) 2017-03-15 2019-11-29 潘迪恩治疗公司 靶向免疫耐受性
EP3606946B1 (en) * 2017-04-03 2022-08-24 F. Hoffmann-La Roche AG Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
CN110382525B (zh) * 2017-04-03 2023-10-20 豪夫迈·罗氏有限公司 免疫缀合物
KR102364599B1 (ko) 2017-04-04 2022-02-21 에프. 호프만-라 로슈 아게 Cd40 및 fap에 특이적으로 결합할 수 있는 새로운 이중특이적 항원 결합 분자
EP4516809A2 (en) 2017-04-05 2025-03-05 F. Hoffmann-La Roche AG Bispecific antibodies specifically binding to pd1 and lag3
JP6928668B2 (ja) 2017-04-11 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 増大した熱安定性を有する変異型逆転写酵素、ならびにそれに関する生成物、方法および使用
EP3609537A1 (en) 2017-04-13 2020-02-19 H. Hoffnabb-La Roche Ag An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
CN111010866A (zh) 2017-05-24 2020-04-14 潘迪恩治疗公司 靶向免疫耐受性
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
KR20200010468A (ko) 2017-05-24 2020-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
CN111107868A (zh) * 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
CA3067603A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
TWI821192B (zh) 2017-07-11 2023-11-11 美商新索思股份有限公司 非天然核苷酸之導入及其方法
KR102708105B1 (ko) * 2017-08-03 2024-09-24 신톡스, 인크. 자가면역 질환의 치료를 위한 사이토카인 접합체
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN112272563A (zh) 2017-11-08 2021-01-26 Xencor股份有限公司 使用新颖抗pd-1序列的双特异性和单特异性抗体
SG11202004581PA (en) 2017-11-21 2020-06-29 Univ Leland Stanford Junior Partial agonists of interleukin-2
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
JP7336457B2 (ja) * 2017-12-26 2023-08-31 ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド 抗体Ｆｃ領域を主鎖として用いた融合タンパク質二量体及びその使用
EP3732187A4 (en) 2017-12-29 2021-11-10 The Scripps Research Institute PAIRING COMPOSITIONS OF NON-NATURAL BASES AND METHODS OF USE
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US20200354424A1 (en) 2018-01-26 2020-11-12 Orionis Biosciences, Inc. Xcr1 binding agents and uses thereof
MX2020008208A (es) 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
AU2019218959A1 (en) 2018-02-08 2020-09-03 Genentech, Inc. Bispecific antigen-binding molecules and methods of use
US20210260163A1 (en) 2018-03-09 2021-08-26 AskGene Pharma, Inc. Novel cytokine prodrugs
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210024602A1 (en) * 2018-03-28 2021-01-28 Ascendis Pharma Oncology Division A/S IL-2 Conjugates
SG11202009017WA (en) 2018-03-28 2020-10-29 Bristol Myers Squibb Co Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020020783A1 (en) * 2018-07-24 2020-01-30 Biontech Rna Pharmaceuticals Gmbh Il2 agonists
CN117925531A (zh) 2018-08-01 2024-04-26 南克维斯特公司 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
SG11202102427XA (en) * 2018-09-11 2021-04-29 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
MX2020007072A (es) 2018-09-17 2020-11-11 Gi Innovation Inc Proteina de fusion que comprende proteina il-2 y proteina cd80 y uso de la misma.
TWI846731B (zh) 2018-09-18 2024-07-01 瑞士商赫孚孟拉羅股份公司 組織蛋白酶(cathepsin)S抑制劑之對抗抗藥抗體形成之用途
WO2020057646A1 (zh) * 2018-09-21 2020-03-26 信达生物制药(苏州)有限公司 新型白介素2及其用途
EP3854805A4 (en) * 2018-09-21 2022-08-24 Innovent Biologics (Suzhou) Co., Ltd. NOVEL INTERLEUKIN 2 AND ITS USE
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
CN113195523A (zh) 2018-10-03 2021-07-30 Xencor股份有限公司 IL-12异源二聚体Fc融合蛋白
MX2021004711A (es) * 2018-10-23 2021-07-02 Dragonfly Therapeutics Inc Proteinas heterodimericas fusionadas con fragmento cristalizable (fc).
CN113166272B (zh) * 2018-10-29 2024-07-23 北京强新生物科技有限公司 新型合理设计的蛋白质组合物
BR112021010983A2 (pt) * 2018-12-21 2021-08-31 Jiangsu Hengrui Medicine Co., Ltd. Variante de interleucina-2 humana ou seu derivado
EP3901167A4 (en) * 2018-12-21 2022-11-16 Hanmi Pharm. Co., Ltd. NEW IMMUNOSUPPRESSIVE INTERLEUKIN 2
US20220025050A1 (en) 2018-12-21 2022-01-27 Ose Immunotherapeutics Bifunctional molecule directed against human pd-1
CA3123493A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted agonistic cd28 antigen binding molecules
MX2021008147A (es) * 2019-01-07 2021-08-11 Inhibrx Inc Polipeptidos que comprenden polipeptidos con il-2 modificada y usos de los mismos.
TW202038994A (zh) * 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
MA54952A (fr) 2019-02-06 2022-05-11 Synthorx Inc Conjugués d'il-2 et méthodes d'utilisation de ceux-ci
CN114026122B (zh) 2019-02-21 2024-12-31 马伦戈治疗公司 结合t细胞相关癌细胞的多功能分子及其用途
CN120230213A (zh) 2019-03-01 2025-07-01 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
CN111647068A (zh) * 2019-03-04 2020-09-11 江苏恒瑞医药股份有限公司 一种人白细胞介素2变体或其衍生物
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN111944008A (zh) * 2019-05-14 2020-11-17 上海盖浦生物科技有限公司 一种突变蛋白的方法以及得到的突变体蛋白
US20220241375A1 (en) 2019-05-20 2022-08-04 Cytune Pharma Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
TW202110885A (zh) 2019-05-20 2021-03-16 美商潘迪恩治療公司 靶向ＭＡｄＣＡＭ之免疫耐受性
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
IL288941B1 (en) 2019-06-14 2025-06-01 Scripps Research Inst Reagents and methods for replication, transcription, and translation in semisynthetic organisms
US20220170028A1 (en) * 2019-06-14 2022-06-02 Cugene Inc Novel interleukin-2 variants and bifunctional fusion molecules thereof
TW202115105A (zh) * 2019-06-24 2021-04-16 德商拜恩迪克Ｒｎａ製藥有限公司 Ｉｌ２激動劑
TW202115115A (zh) 2019-07-02 2021-04-16 瑞士商赫孚孟拉羅股份公司 免疫結合物
MX2022000991A (es) * 2019-07-25 2022-05-24 Univ Chicago Composiciones y metodos que comprenden agentes terapeuticos activados por proteasa.
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
US20220306714A1 (en) * 2019-08-12 2022-09-29 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
CA3147291A1 (en) 2019-08-15 2021-02-18 Igm Biosciences, Inc. Immunostimulatory multimeric binding molecules
US12234271B2 (en) 2019-09-10 2025-02-25 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
WO2021055568A1 (en) * 2019-09-19 2021-03-25 Proviva Therapeutics (Hong Kong) Limited Il-2 compositions and methods of use thereof
EP4034144A1 (en) 2019-09-27 2022-08-03 Intrexon Actobiotics NV d/b/a Precigen Actobio Treatment of celiac disease
CN117004564A (zh) 2019-11-20 2023-11-07 吉爱希公司 调节性t细胞培养组合物及其用途
JP7543404B2 (ja) 2019-11-20 2024-09-02 ジーアイ・セル・インコーポレイテッド Ｔ細胞培養用培地組成物及びこれを用いたｔ細胞の培養方法
EP4063491B1 (en) 2019-11-20 2024-11-13 GI Cell, Inc. Composition for culturing natural killer cells and method for preparing natural killer cells by using same
CN114746544A (zh) 2019-11-27 2022-07-12 吉爱希公司 用于治疗癌症的、包含含有il-2蛋白和cd80蛋白的融合蛋白与自然杀手细胞的药物组合物
WO2021107689A1 (ko) * 2019-11-27 2021-06-03 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물
BR112022011949A2 (pt) 2019-12-17 2022-11-22 Amgen Inc Dupla de interleucina-2/agonista do receptor tnf para uso em terapia
CN114478743A (zh) 2019-12-17 2022-05-13 北京志道生物科技有限公司 白介素-2衍生物
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
US20230201283A1 (en) * 2020-01-09 2023-06-29 Pfizer Inc. Recombinant vaccinia virus
CN115315436A (zh) 2020-01-10 2022-11-08 明峰治疗股份公司 修饰的il-2多肽及其用途
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine, Inc. METHODS AND COMPOSITIONS OF BIASED IL2 MUTEINS
AU2021207901A1 (en) 2020-01-14 2022-09-08 Synthekine, Inc. IL2 orthologs and methods of use
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
TWI839476B (zh) * 2020-02-26 2024-04-21 大陸商北京泰德製藥股份有限公司 介白素-2多肽共軛物及其用途
CN115461071A (zh) * 2020-03-05 2022-12-09 小利兰·斯坦福大学托管委员会 设计的il-2变体
WO2021187904A1 (ko) 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질 단편 또는 이의 변이체를 포함하는 융합단백질 및 이의 용도
WO2021187897A1 (ko) 2020-03-18 2021-09-23 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 제제
TWI855242B (zh) 2020-03-18 2024-09-11 南韓商Ｇｉ醫諾微新股份有限公司 包含含有il-2蛋白與cd80蛋白之融合蛋白及抗癌藥物的用於治療癌症的藥學組成物
CN115698052A (zh) * 2020-03-19 2023-02-03 信达生物制药(苏州)有限公司 白介素2突变体及其用途
JP2023518443A (ja) 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
WO2021202675A1 (en) * 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-2 cytokines and their cleavage products
BR112022020629A2 (pt) 2020-04-15 2022-11-29 Hoffmann La Roche Polipeptídeo de interleucina-7 (il-7) mutante, imunoconjugado, um ou mais polinucleotídeos isolados, célula hospedeira, métodos para produzir um polipeptídeo il-7 mutante ou um imunoconjugado, para tratar uma doença e para estimular o sistema imunológico, polipeptídeo il-7 mutante, composição farmacêutica, uso do polipeptídeo il-7 mutante e invenção
EP4139341A1 (en) 2020-04-21 2023-03-01 Regeneron Pharmaceuticals, Inc. Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
JP7415047B2 (ja) 2020-04-22 2024-01-16 メルク・シャープ・アンド・ドーム・エルエルシー インターロイキン－２受容体βγｃ二量体について偏向され、非ペプチド性水溶性ポリマーにコンジュゲートされたヒトインターロイキン－２コンジュゲート
BR112022022614A2 (pt) 2020-05-11 2023-02-07 Hoffmann La Roche Métodos para estimular uma resposta imune, melhorar uma imunoterapia, tratar uma doença, reduzir crescimento tumoral, produzir um imunoconjugado e produzir uma composição, método de vacinação, imunoconjugados, composição, usos e kits
JP2023526723A (ja) 2020-05-12 2023-06-23 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
GB2602612B (en) 2020-05-13 2023-11-01 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
CN113667004A (zh) * 2020-05-14 2021-11-19 上海盖浦生物科技有限公司 一种白介素2突变体
US20230174605A1 (en) 2020-06-03 2023-06-08 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
KR102373965B1 (ko) 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
US11780920B2 (en) 2020-06-19 2023-10-10 Hoffmann-La Roche Inc. Antibodies binding to CD3 and CD19
KR20230025783A (ko) 2020-06-19 2023-02-23 에프. 호프만-라 로슈 아게 면역 활성화 Fc 도메인 결합 분자
EP4174088A4 (en) 2020-06-30 2024-01-24 GI Innovation, Inc. FUSION PROTEIN WITH ANTI-LAG-3 ANTIBODIES AND IL-2 AND USE THEREOF
KR20220014531A (ko) * 2020-07-29 2022-02-07 (주)메디톡스 헤테로이량체 Ｆｃ 융합 단백질, 및 관련 조성물, 용도 및 방법
TW202221031A (zh) 2020-07-30 2022-06-01 英商阿法克塔生命科學有限公司 血清半衰期延長之pd-l1抑制多肽
MX2023001962A (es) 2020-08-19 2023-04-26 Xencor Inc Composiciones anti-cd28.
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN117500518A (zh) * 2020-09-18 2024-02-02 地方独立行政法人 宫城县立医院机构 Il-2突变蛋白及包含其的药物
CN114369153A (zh) * 2020-10-18 2022-04-19 北京志道生物科技有限公司 一种白介素-2突变体
CN118598977A (zh) * 2020-10-18 2024-09-06 北京志道生物科技有限公司 经修饰的il-2分子及其用途
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
MX2023004879A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DEL CARCINOMA DE CÉLULAS ESCAMOSAS.
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
US20240325495A1 (en) 2020-10-29 2024-10-03 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
CN114437228B (zh) * 2020-10-30 2024-02-06 中国科学院生物物理研究所 一种il-2与抗体亚单位构成的双功能融合蛋白
KR20230107598A (ko) 2020-11-13 2023-07-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인간 인터루킨 2 변이체 또는 이의 유도체를 포함하는 약학적 조성물 및 이의 용도
CN112724259B (zh) * 2020-11-16 2022-12-20 天津林达生物科技有限公司 人血清白蛋白与白介素2的融合蛋白及其用途
TW202235431A (zh) 2020-11-25 2022-09-16 美商艾希利歐發展股份有限公司 腫瘤特異性可裂解連接子
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
AU2021393752A1 (en) 2020-12-04 2023-05-18 F. Hoffmann-La Roche Ag Ph-dependent mutant interleukin-2 polypeptides
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
AU2022210419A1 (en) * 2021-01-19 2023-07-20 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
JP2024512382A (ja) 2021-03-09 2024-03-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１標的化ｉｌ－２バリアント免疫コンジュゲートと抗ｔｙｒｐ１／抗ｃｄ３二重特異性抗体の併用療法
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
CA3209640A1 (en) 2021-03-09 2022-09-15 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
CN117321087A (zh) 2021-03-26 2023-12-29 先天制药公司 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
JP2024512709A (ja) 2021-03-30 2024-03-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト プロテアーゼ活性化ポリペプチド
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
CN116854802A (zh) * 2021-04-13 2023-10-10 苏州复融生物技术有限公司 白介素2突变体及其应用
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
IL308531A (en) 2021-06-09 2024-01-01 Innate Pharma Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
JP2024521405A (ja) 2021-06-09 2024-05-31 イナート・ファルマ・ソシエテ・アノニム Ｎｋｐ４６、サイトカイン受容体、腫瘍抗原およびｃｄ１６ａに結合する多特異性タンパク質
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
EP4366781A1 (en) 2021-07-09 2024-05-15 Bright Peak Therapeutics AG Checkpoint inhibitors conjugated to il-2, and uses thereof
CA3222359A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
AU2022306145A1 (en) 2021-07-09 2024-02-01 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20240368238A1 (en) * 2021-07-30 2024-11-07 Dracoterpin Biomedicine Llc Human interleukin-2 variant and use thereof
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
AU2022332499A1 (en) 2021-08-24 2024-03-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fap/cd40 binding molecule and medicinal use thereof
KR20240067081A (ko) * 2021-09-26 2024-05-16 우시 바이올로직스 아일랜드 리미티드 Il-2 변이체 및 이의 융합 단백질
CA3234731A1 (en) 2021-10-14 2023-04-20 F. Hoffmann-La Roche Ag New interleukin-7 immunoconjugates
CN118139648A (zh) 2021-10-14 2024-06-04 豪夫迈·罗氏有限公司 用于治疗癌症的替代的PD1-IL7v免疫缀合物
CU20210104A7 (es) 2021-12-21 2023-07-12 Ct Inmunologia Molecular Proteínas de fusión compuestas por un anticuerpo y una muteína agonista de interleucina 2
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20230303650A1 (en) * 2022-01-21 2023-09-28 Aetio Biotherapy, Inc. Immunoconjugates of Interlukin-2 Mutant Polypeptides with Antibodies
JP2024515912A (ja) * 2022-02-21 2024-04-11 シーティーセルズ、インコーポレイテッド 抗原結合ドメインおよびサイトカイン三量体ドメインを含む融合タンパク質
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
CN116769013A (zh) * 2022-03-10 2023-09-19 广东菲鹏制药股份有限公司 白细胞介素2突变体以及含有其的复合物
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
WO2023245097A2 (en) 2022-06-16 2023-12-21 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
TW202409069A (zh) * 2022-07-01 2024-03-01 大陸商北京星奇原生物科技有限公司 Ｉｌ－２多肽和使用方法
EP4556493A1 (en) 2022-07-11 2025-05-21 Genuv Inc. Cytokine fusion protein
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
TWI875131B (zh) * 2022-08-16 2025-03-01 國立陽明交通大學 介白素-2變異體及其於治療癌症的用途
CN119948048A (zh) 2022-09-29 2025-05-06 豪夫迈·罗氏有限公司 蛋白酶活化的多肽
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
WO2024119193A2 (en) 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
US20240376170A1 (en) 2023-01-11 2024-11-14 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
WO2024153722A1 (en) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Immunoconjugates
WO2024215989A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. ENGINEERED IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-2/IL-15 RECEPTOR βγ AGONISTS
TW202509065A (zh) 2023-05-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 經ｐｄ－１調節之ｉｌ－２免疫結合物及其用途
WO2024251884A1 (en) 2023-06-09 2024-12-12 Innate Pharma Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
WO2025137093A1 (en) 2023-12-19 2025-06-26 Cephalon Llc Uses for attenuated il-2 immunoconjugates

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7802170A (nl) 1977-04-18 1978-10-20 Hitachi Metals Ltd Sierraad.
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
EP0229108B1 (en) 1985-06-26 1990-12-27 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE19607751A1 (de) 1996-02-29 1997-09-04 Henkel Kgaa Neue Aminophenol-Derivate und deren Verwendung
KR100628846B1 (ko) 1996-10-18 2006-09-29 제넨테크, 인크. 항-ＥｒｂＢ２ 항체
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
EP1071700B1 (en) 1998-04-20 2010-02-17 GlycArt Biotechnology AG Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
JP4841727B2 (ja) 1999-02-12 2011-12-21 ザ スクリプス リサーチ インスティチュート 抗血管新生治療及び免疫治療の組み合わせを用いる腫瘍及び転移の治療方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
EP1268550A2 (en) 2000-03-17 2003-01-02 Boehringer Ingelheim Pharma KG Human fap-alpha-specific antibodies
JP4936299B2 (ja) 2000-08-21 2012-05-23 メレクシス・テクノロジーズ・ナムローゼフェンノートシャップ 磁場方向検出センサ
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
ATE471344T1 (de) 2001-04-13 2010-07-15 Biogen Idec Inc Antikörper gegen vla-1
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP1476180A4 (en) 2001-08-13 2005-04-20 Univ Southern California MUTANTS OF INTERLEUKIN-2 WITH REDUCED TOXICITY
CA2469151C (en) * 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
ES2543734T3 (es) 2003-01-22 2015-08-21 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2005062929A2 (en) 2003-12-22 2005-07-14 Chiron Coporation Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
RU2006135112A (ru) * 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) Тест-система in vitro для прогнозирования устойчивости пациента к терапевтическим средствам
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
AU2006246061A1 (en) * 2005-05-11 2006-11-16 Philogen S.P.A. Fusion protein of antibody L19 against fibronectin ED-B and interleukin 12
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
KR20090008467A (ko) 2006-05-08 2009-01-21 필로겐 에스.피.에이. 치료용의 항체­표적 사이토카인
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
AR062223A1 (es) 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
PT2066796E (pt) 2006-09-20 2011-10-11 Mt Biomethan Gmbh Procedimento e dispositivo para a separação do metano e do dióxido de carbono do biogás
WO2008065372A2 (en) 2006-11-28 2008-06-05 Nautilus Biotech, S.A. Modified erythropoietin polypeptides and uses thereof for treatment
AU2008254951A1 (en) * 2007-05-14 2008-11-27 Biogen Idec Ma Inc. Single-chain Fc (ScFc) regions, binding polypeptides comprising same, and methods related thereto
EP2183028A2 (en) 2007-07-25 2010-05-12 AstraZeneca AB Targeted binging agents directed to kdr and uses thereof - 035
EP2018877A1 (en) 2007-07-27 2009-01-28 The Procter and Gamble Company Absorbent article comprising water-absorbing polymeric particles and method for the production thereof
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
ATE548052T1 (de) 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
EP2271364B1 (en) 2008-04-10 2016-08-10 IBC Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology
PT2285416E (pt) 2008-05-13 2012-07-26 Molmed Spa Conjugados para o tratamento de mesotelioma
US20110274650A1 (en) * 2009-01-21 2011-11-10 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
AU2010208125B2 (en) * 2009-01-29 2015-02-12 Medimmune, Llc Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
AU2010230063B2 (en) * 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
WO2010117448A2 (en) 2009-04-05 2010-10-14 Provenance Biopharmaceuticals Corp. Chimeric immunocytokines and methods of use thereof
EP2448599A1 (en) 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
MX2012002014A (es) * 2009-08-17 2012-06-13 Roche Glycart Ag Inmunoconjugados dirigidos.
JP5744872B2 (ja) 2009-08-31 2015-07-08 ロシュ グリクアート アーゲー 親和性成熟ヒト化抗ｃｅａモノクローナル抗体
CN102574921B (zh) 2009-09-29 2016-05-04 罗切格利卡特公司 双特异性死亡受体激动型抗体
PE20171512A1 (es) 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
CU23923B1 (es) 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
EA033369B1 (ru) 2011-02-10 2019-10-31 Roche Glycart Ag Мутантные полипептиды интерлейкина-2 со сниженной аффинностью к высокоаффинному рецептору il-2 и неизменной аффинностью к рецептору il-2 с промежуточной аффинностью и их применение
PL2681244T3 (pl) 2011-03-02 2018-04-30 Roche Glycart Ag Przeciwciała przeciwko antygenowi rakowo-płodowemu
PT2691417T (pt) 2011-03-29 2018-10-31 Roche Glycart Ag Variantes de fc de anticorpos
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2700978T3 (es) 2012-08-07 2019-02-20 Roche Glycart Ag Composición que comprende dos anticuerpos genomanipulados para que tengan una función efectora reducida e incrementada
WO2014023673A1 (en) 2012-08-08 2014-02-13 Roche Glycart Ag Interleukin-10 fusion proteins and uses thereof
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014180754A1 (en) 2013-05-07 2014-11-13 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules
CA2951604A1 (en) 2014-08-29 2016-03-03 Pablo Umana Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1

Also Published As

Publication number Publication date
KR20130118363A (ko) 2013-10-29
HRP20181736T1 (hr) 2018-12-28
ES2883371T3 (es) 2021-12-07
ES2694564T3 (es) 2018-12-21
CN103492411A (zh) 2014-01-01
LT3489255T (lt) 2021-08-25
NZ611749A (en) 2015-08-28
TW201718029A (zh) 2017-06-01
EP3489255B1 (en) 2021-06-16
JP2014506793A (ja) 2014-03-20
EP2673294A1 (en) 2013-12-18
LT3075745T (lt) 2018-11-26
EA201300896A1 (ru) 2014-02-28
CY1117842T1 (el) 2017-05-17
PL3489255T3 (pl) 2021-11-22
US20190322765A1 (en) 2019-10-24
PL2673294T3 (pl) 2016-11-30
JP2015229676A (ja) 2015-12-21
KR101852245B1 (ko) 2018-04-25
IL252230B (en) 2019-10-31
ZA201305282B (en) 2016-07-27
PE20181077A1 (es) 2018-07-05
HUE029139T2 (hu) 2017-02-28
HUE055284T2 (hu) 2021-11-29
DK2673294T3 (en) 2016-05-30
NZ710742A (en) 2017-04-28
BR112013018932B1 (pt) 2020-11-17
RS54802B1 (sr) 2016-10-31
AU2012215573B2 (en) 2015-11-26
BR112013018932A2 (pt) 2017-05-02
PT2673294T (pt) 2016-07-07
SG192673A1 (en) 2013-09-30
US20190077881A1 (en) 2019-03-14
AU2015249085B2 (en) 2017-12-14
CO6741186A2 (es) 2013-08-30
US10184009B2 (en) 2019-01-22
AR085335A1 (es) 2013-09-25
EP3075745A1 (en) 2016-10-05
TWI666027B (zh) 2019-07-21
PH12017500954A1 (en) 2017-11-27
SG10201604160WA (en) 2016-07-28
CN105440123A (zh) 2016-03-30
PT3489255T (pt) 2021-08-13
IL269687B (en) 2022-08-01
US20160208017A1 (en) 2016-07-21
ES2579987T3 (es) 2016-08-18
RS57767B1 (sr) 2018-12-31
CN103492411B (zh) 2016-12-07
WO2012107417A1 (en) 2012-08-16
EP3971206A1 (en) 2022-03-23
KR20150092367A (ko) 2015-08-12
CA2824253A1 (en) 2012-08-16
HK1217020A1 (zh) 2016-12-16
KR101667096B1 (ko) 2016-10-18
IL252230A0 (en) 2017-07-31
CN105440123B (zh) 2020-10-09
MX356675B (es) 2018-06-08
AU2012215573A1 (en) 2013-05-02
RS62238B1 (sr) 2021-09-30
US20180142037A1 (en) 2018-05-24
HRP20160917T1 (hr) 2016-09-23
CN112210000A (zh) 2021-01-12
MA35803B1 (fr) 2014-12-01
PH12013501657A1 (en) 2013-10-07
UA117294C2 (uk) 2018-07-10
IL269687A (en) 2019-11-28
EP3489255A1 (en) 2019-05-29
CR20130314A (es) 2013-08-09
SI3075745T1 (sl) 2018-12-31
MY190604A (en) 2022-04-27
HUE040326T2 (hu) 2019-03-28
PH12017500954B1 (en) 2020-06-03
PT3075745T (pt) 2018-11-14
TWI577801B (zh) 2017-04-11
US11111312B2 (en) 2021-09-07
UA113729C2 (xx) 2017-03-10
SI2673294T1 (sl) 2016-08-31
ECSP13012815A (es) 2013-10-31
EA033369B1 (ru) 2019-10-31
EP3075745B1 (en) 2018-09-05
DK3075745T3 (en) 2018-11-26
US20120244112A1 (en) 2012-09-27
MX2013009226A (es) 2013-12-06
AU2015249085A1 (en) 2015-11-12
TW201237165A (en) 2012-09-16
US9266938B2 (en) 2016-02-23
SI3489255T1 (sl) 2021-11-30
PL3075745T3 (pl) 2019-07-31
JP6155300B2 (ja) 2017-06-28
MX340671B (es) 2016-07-20
US10323098B2 (en) 2019-06-18
IL227095B (en) 2018-06-28
EP2673294B1 (en) 2016-04-27
PE20140303A1 (es) 2014-03-22
CA2824253C (en) 2019-09-17
HRP20211318T1 (hr) 2021-11-26
JP5878182B2 (ja) 2016-03-08
DK3489255T3 (da) 2021-08-23

Similar Documents

Publication Publication Date Title
CL2013001987A1 (es) Polipeptidos interleuquina-2 mutante que comprende una primera mutacion de aminoacido que anula o reduce la afinidad del polipeptido il-2 mutante para receptor il-2 de alta afinidad y conserva afinidad del polipeptido il-2 mutante para receptor il-2 de afinidad intermedia; inmunoconjugado; metodo para producir polipeptido; composicion farmaceutica que lo comprende.
EP3309177A4 (en) Pdl-1 antibody, pharmaceutical composition thereof, and uses thereof
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
BR112014010023A2 (pt) método in vitro para à produção de uma proteína heterodimérica, e, sequência de nucleotídeo
EP2709603A4 (en) MODIFIED BIOTIN-BINDING PROTEIN, FUSION PROTEINS AND APPLICATIONS THEREWITH
CL2017002283A1 (es) Formulaciones de anticuerpos y métodos (divisional de solicitud n°1081-2014)
WO2012034039A3 (en) Anti-il-1 beta antibodies and methods of use
CL2013001107A1 (es) Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
IL233050A0 (en) New drug-antibody conjugates and their use
HK1213581A1 (zh) 抗-cd40抗體及其使用方法
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
BR112013001831B8 (pt) partículas abrasivas formatadas
BR112014010177A2 (pt) composto, composição farmacêutica, uso do composto, e, método para a profilaxia ou tratamento de um estado ou uma condição de doença
MX381232B (es) Formulación de anticuerpos.
MX2013009679A (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
EP2683968A4 (en) SEAL ASSEMBLY FOR PISTON AND TURNING APPLICATIONS
EP2896705A4 (en) CU-AL-MN BASE ALLOY MATERIAL WITH STABLE SUPER-ELASTICITY AND METHOD OF MANUFACTURING THEREOF
IL222270A (en) A monoclonal antibody or its segment, which is linked to a full-length human lif, a medical component that includes it and a process for preparing it
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
IL232867B (en) Amyloid-binding polypeptide and chimeric protein containing it, pharmaceutical preparations containing the polypeptide or chimeric protein, methods for their preparation and uses
BRPI1008885A2 (pt) anticorpo, método para a produção de um anticorpo, uso do anticorpo, método para a produção de polipeptídeo de neurotoxina processado, métoro para a produção de um medicamento e composição
BR112014016744A2 (pt) polipeptídeo, composição farmacêutica e método para a produção de um ou mais polipeptídeos
CL2013003285A1 (es) Cepas de salmonella gallinarum modificadas avirulentas; composicion farmaceutica que la usan; aditivo para piensos; procedimiento de tratamiento de la tifosis aviar infecciosa por salmonella gallinarum.
EP2795692A4 (en) METHOD AND MATERIALS FOR PRODUCING RESTRICTED LAYERS AND DEVICES MADE THEREFOR